Image Caption: Converging AI and Blockchain technologies to return the control over human life data to the patients and accelerate biomedical research
Blockchain and AI researchers propose a new model to return the control over
human life data to the patients and accelerate biomedical research
Embargoed until: Wednesday, 15th of November, 2017, 10AM EST, Baltimore, MD, Insilico
Medicine, a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery announced the publication of a new
peer-reviewed research paper titled” Converging blockchain and next-generation artificial
intelligence technologies to decentralize and accelerate biomedical research and healthcare” in Oncotarget (insert the link here). Insilico Medicine scientists specializing in deep learning
collaborated with the scientists and developers from BitFury Groups, one of the largest
companies in blockchain technology producing its own semiconductors, transitioning the entire national government systems onto blockchain. In the paper the groups presented the first
attempt to assess the value of time and the combination value of personal data in the context of an AI-mediated health data exchange on blockchain.
“Most people do not understand what life data data they have, how valuable and dangerous this data may be and do not have any control over how their life data is being used. The policy makers are trying to address this problem by introducing new regulations that make it expensive and difficult for the innovators to turn the human life data into life-saving products. In this paper we propose a blockchain-enabled solution to help people become aware of and take control over their data and profit from licensing the data to the innovators”, said Polina Mamoshina, Sr. research scientist at Insilico Medicine.
In this research paper scientists introduce new concepts to appraise and evaluate human life
data, including the combination-, time- and relationship-value of the data and present a
roadmap for a blockchain-enabled decentralized personal health data ecosystem to enable
novel approaches for drug discovery, biomarker development, and preventative healthcare. A secure and transparent distributed personal data marketplace utilizing blockchain and deep
learning technologies may be able to resolve the challenges faced by the regulators and return the control over personal data including medical records back to the individuals.
QUOTE FROM BITFURY
Blockchain technology enables the creation of a distributed and secure ledger of personal data, where patients are in control, own their data, and monitoring of access privileges and
understanding of who looked at the data. Most importantly, blockchain technology allows for the creation of a data-driven marketplace, where patients can earn tangible rewards for making their data available to the application development community, pharmaceutical and consumer companies, and research institutions and generating new data through regular and
comprehensive tests and checkups. Presently, only a few patients worldwide have the
comprehensive data sets containing their clinical history combined with the genetic, blood
biochemistry and cell count profiles, lifestyle data, drug and supplement use and other data
types, because they do not see the value in this data and do not get tested regularly. On the other hand, the pharmaceutical and consumer companies alike are willing to pay substantial amounts for the large numbers of personal data records required to train their AI. These funds can be used to subsidize the regular testing by the patients, uncover the new uses for the various data types and develop sophisticated diagnostic and treatment tools.
“In the post neoclassical world, healthy productive longevity will be the new driver of economic growth. Creating an economy around human life data and returning the ownership and the control over life data back to the individual is one of the most important steps towards extending healthy productive longevity of the global population. It is also a very altruistic cause, which may help reduce the gap between the rich and the poor and allow the people from all walks of life and geographies to equally profit from their own data”, said Alex Zhavoronkov, the founder of Insilico Medicine, Inc.
For further information, images or interviews, please contact:
Contact: Qingsong Zhu, PhD
About Insilico Medicine, Inc
Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Russia, and the UK sourced through hackathons and competitions.
The company utilizes advances in genomics, big-data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company is pursuing internal drug discovery programs in cancer, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging.
Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies, foundations and national governments globally. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. http://www.insilico.com